NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

May 5, 2023

Study Completion Date

May 5, 2023

Conditions

Accelerated Phase CML, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Phase CML, BCR-ABL1 PositiveCOVID-19 InfectionHematopoietic and Lymphoid Cell NeoplasmHodgkin LymphomaLymphoblastic LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmNon-Hodgkin Lymphoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of nasopharyngeal swabs, blood, and saliva samples

OTHER

Diagnostic Laboratory Biomarker Analysis

Correlative studies

OTHER

Electronic Health Record Review

Medical charts are reviewed

OTHER

Questionnaire Administration

Complete questionnaire

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER